180 Life Sciences is developing new treatments for one of the world’s biggest drivers of disease: inflammation
· Stock symbol #ATNF
· All insiders fully invested ( the last was today)
· 46%+ Ownership by Management and Insiders
· Best risk/reward biotech plays
· The top selling drug class in the world (Remicade, Embrel, Humira,etc)
· Under the radar
· Less than 1 year public
· Market cap under 250M
· Stellar management team
· Strong IP portfolio with a long lifespan, providing coverage up to 2039
· Blockbuster pipeline
· Multibagger stock
· Low float
· Very undervalued
· Great short/long term investment
· Possible short squeeze candidate
· Largest shareholders include Ionic Capital Management LLC, Vanguard Group Inc, Cnh Partners Llc, ADANX – AQR Diversified Arbitrage Fund Class N, Goldman Sachs Group Inc, Susquehanna International Group, Llp, Boothbay Fund Management, Llc, BlueCrest Capital Management Ltd, VTSMX – Vanguard Total Stock Market Index Fund Investor Shares, and BlackRock Inc..
| Q3/4 | Results of Early stage Dupuytren’s disease Phase 2b/3 Clinical Trial ( it is possible that the results will be presented at the BSSH conference in September) |
|---|---|
| Sept 9 | Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK |
| Aug 10 | ATNF participation at BTIG Virtual Biotechnology Conference Fireside Chat |
| Jul 28 | ATNF Announces Selection of Lead Synthetic CBD Analogue |
| Jul 20 | ATNF Regains fully Nasdaq Compliance |
| Jul 07 | ATNF Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal |
| June 28 | ATNF Joins Russell Microcap® Index |
| Apr 14 | Lynn Williams, Ph.D., has been awarded the International Dupuytren Award 2023 for Basic Research |
$ATNF is an excellent investment. The founders pioneered blockbuster anti-inflammatory drugs Remicade and Humira. Primary Active ingredient for Dupuytren’s Contracture is same drug already approved for another indication— Rheumatoid Arthritis the single largest market in pharmaceuticals. Read that last sentence again the founders discovered the biology behind anti TNF and are world famous academics including a winner of The Lasker Prize. Because the research was done on this P2B/ P3 on diseased human Dupuytren’s tissue the move straight to FDA drug submission upon proof of concept. Other indications being targeted in future in order are Frozen shoulder, POST Operative Cognitive Decline, NonAlcoholic Steatohepatitis (Fatty Liver Disease) and Ulcerative Colitis brought on by smoking cessation. Another pathway being targeted is pain and inflammation using SCA’s— synthetic cannabinol diet analogues. You see a founder is the Israeli scientist who first isolated THC and discovered the human endocannabinoid system. Known as godfather of cannabis. Some of you apes might be familiar with the stuff. But it’s synthetic and pure now think about pairing pain relief for musculoskeletal pain with the anti TNF meds proven effective on rheumatoid arthritis and consider that market. Get the picture. Now the CEO has a history of allowing data on patented medication to be released in academic setting. By the way current patents are worth more than stock price. So the catalyst of a keynote address at Oxford to the royal society of hand surgeons is the very stage for release if data. Oxford is also home to founder Sir Ralph Winner of Lasker prize. So do you think Anyone at FDA is denying a NDA for a medication already wildly successful for new indications for which there are no treatments. I don’t think so. It’s like telling Einstein E=MC squared is wrong. There is no one at FDA who can challenge the science.
Scientific team and founders are pioneers with proven track record in drug discovery from the University of Oxford, Hebrew University and Stanford University.
Fibrosis and Anti-TNF
The fibrosis and anti-TNF program is based at the Kennedy Institute, at the University of Oxford in the UK.The team is led by Professor Jagdeep Nanchahal, a surgeon-scientist who has been running the phase 2b/3 trials, and Professor Sir Marc Feldmann, a renowned immunologist and one of the pioneers of anti-TNF therapy. Feldmann was instrumental in developing infliximab (Remicade) as a treatment for rheumatoid arthritis, now one of the best-selling drugs in the world and the main driver behind Johnson & Johnson’s $4.9 billion acquisition of Centocor in 1998.
TARGETED DISEASES
• Early stage Dupuytren’s disease (DD)
• Frozen Shoulder
• Post Operative Delirium/Cognitive Deficit (POCD) FURTHER OUT
• Non-Alcoholic Steatohepatitis (NASH)Synthetic CBD Analogs (SCAs)
180 Life Sciences aims to develop SCAs that are safe, non-psychoactive and formulated to improve efficacy and bioavailability – a real alternative to unregulated cannabidiol (CBD).This program is led by Professor Raphael Mechoulam, who discovered tetrahydrocannabinol (THC), the psychoactive component in cannabis, and the endocannabinoid system.Typical botanical derived CBD contains impurities such as THC (the psychoactive compound within cannabis) and other minor cannabinoids. By developing SCAs, 180 Life Sciences will create a pure compound (>99.5%) which offers accurate consistency across batches. Combined with novel formulations through use of patented ProNanoLipospheres (PNL), 180LS will deliver a superior CBD analogue that offers improved efficacy and bioavailability.These conditions create greater likelihood for obtaining regulatory approval.
TARGETED DISEASES
• Arthritis
• Pain/Inflammationα7nAChR
Nicotine binds α7nAChR and is a known immune suppressive. A subgroup of patients who cease smoking go on to acquire ulcerative colitis. 180 Life Sciences believes that α7nAChR agonist treatment provides a solution: without the addictive qualities of smoking, an α7-based drug will reduce ulcerative colitis in ex-smokers.Led by Professor Lawrence Steinman and Dr Jonathan Rothbard, who have been working on this project for more than a decade, 180 Life Sciences is developing a treatment for ulcerative colitis in ex-smokers. α7nAChR holds advantages over existing treatments:
Fewer opportunistic infections
Reduced risk of kidney damage
Higher anticipated success rate
TARGETED DISEASES
• Smoking cessation induced Ulcerative Colitis (UC) initially
• Other inflammatory indications will be targeted after results in UC
Last insider purchase Aug 6:
More information
company website: https://180lifesciences.com
lots of information: ATNF 180 Life Sciences Corp — Stock Price and Discussion | Stocktwits
youtube: This LEGENDARY biotech stock is 22x UNDERVALUED – YouTube
This article was written by u/CZHawkeye
